The Bone and Mineral Manual: A Practical Guide

Cover
Michael Kleerekoper, Ethel S. Siris, Michael McClung
Elsevier, 23.08.2005 - 208 Seiten
- Brings together up-to-date bone and mineral metabolism methods in one easily, accessible volume - Provides a quick reference for bone and mineral disorders - Addresses problems likely to be seen at all ages, from the pre-term infant to the centenarian - Ideal for practicing physicians, residents, medical students, and researchers
 

Ausgewählte Seiten

Inhalt

Clinical Disorders
25
Patient and Family Education and Support
173
Index
181
Urheberrecht

Andere Ausgaben - Alle anzeigen

Häufige Begriffe und Wortgruppen

Beliebte Passagen

Seite 43 - syndrome and renal tubular acidosis. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 5th ed. Washington, DC: American Society for Bone and Mineral Research;
Seite 136 - Renal osteodystrophy in adults and children. In: Favus M, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 4th ed. Philadelphia: Lippincott Williams and Wilkins;
Seite 43 - Whyte MP. Hypophosphatasia. In: Scriver CR, Beaudet AL, Sly WS, et al., eds. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill;
Seite 94 - Nieves JW, Komar L, Cosman F, et al. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998;67:18-24.
Seite 59 - Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl]
Seite 43 - Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med
Seite 59 - Shenker A, Weinstein LS, Moran A, et al. Severe endocrine and non-endocrine manifestations of the McCune-Albright syndrome associated with activating mutations of
Seite 78 - The epidemiology of spinal cord injury. In: Stover SL, DeLisa JA, Whiteneck GG, eds. Spinal cord injury: clinical outcomes from the model systems. Gaithersburg:
Seite x - Jean Mayer USDA Human Nutrition Research Center on Aging Tufts University Boston, Massachusetts 02111
Seite 136 - I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int

Autoren-Profil (2005)

Ethel S. Siris, MD, is the Madeline C. Stabile Professor of Clinical Medicine in the Department of Medicine, College of Physicians and Surgeons of Columbia University, and the Director of the Toni Stabile Osteoporosis Center of the Columbia University Medical Center, New York-Presbyterian Hospital, all in New York, New York. She is a graduate of Radcliffe College, Harvard University, and received her medical degree from the College of Physicians and Surgeons of Columbia University. An endocrinologist, she works as a clinician, as a clinical investigator and as a medical educator, all in the area of metabolic bone diseases, including osteoporosis and Paget's disease of bone. In her career she has participated in research activities with bisphosphonates, selective estrogen receptor modulators (SERMS) and RANKL inhibitors. Dr. Siris served as the Medical Director of NORA, the National Osteoporosis Risk Assessment, a public health initiative and longitudinal study of osteoporosis that included over 200,000 postmenopausal women in the US. Most recently her research activity has focused both on risk factors for osteoporosis and treatment adherence with osteoporosis medications. Dr. Siris is the immediate past president of the National Osteoporosis Foundation and currently serves on the Board of Trustees of both the National Osteoporosis Foundation in the US and the International Osteoporosis Foundation. She is also a member and former vice chair of the Board of Directors of the Paget Foundation for Paget's Disease of Bone and Related Disorders. She has previously served on the Council of the American Society for Bone and Mineral Research and on the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration. She has published widely in the medical literature and is co-editor of the book, The Bone and Mineral Manual. Dr. Siris has been interviewed frequently on both television and radio and is often quoted in print media regarding osteoporosis.

Dr. Michael McClung is the founding director of the Oregon Osteoporosis Center. He graduated from Rice University in Houston and from the University of Texas Southwestern Medical School in Dallas. After his training in Internal Medicine at Parkland Hospital in Dallas, he completed a fellowship in Endocrinology at the National Institute of Health in Bethesda, Maryland. He then joined the faculty at the Oregon Health Sciences University, where he is an Associate Professor of Medicine. At OHSU, he founded a clinic devoted to the care of patients with disorders of bone and calcium metabolism that eventually grew into the Oregon Osteoporosis Center. In 1987, Dr. McClung joined the Department of Medical Education at Providence Medical Center where he is actively involved in the training of young physicians. He is board certified in both Internal Medicine and in Endocrinology and Metabolism, and is a fellow of the American College of Endocrinologists and the American College of Physicians. Dr. McClung is an internationally recognized expert in the fields of osteoporosis and bone density testing. His Center has been involved in many of the important clinical studies that resulted in the availability of the medications now used to treat osteoporosis and Paget's disease of bone. He has published more than 200 papers and book chapters, is co-editor of a book for clinicians about disorders of bone and mineral metabolism and is a member of the editorial boards for several journals in his field. Dr. McClung is widely known as an educator, translating clinical research information into practical strategies of evaluation and treatment for other physicians. He is an active member of multiple international societies focusing on bone diseases and their treatment. He serves as a member of the Council of Scientific Advisors for the International Osteoporosis Foundation, on the Scientific Advisory Board of the National Osteoporosis Foundation, and as a medical advisor for the Paget Foundation. He was a member of the World Health Organization Fracture Risk Task Force that led to the development of the FRAX® tool. He is a member of the global advisory boards for multiple companies and organizations. He has served on the Endocrinology and Metabolism Advisory Committee of the FDA and has participated in the development of evidence–based guidelines for the treatment of osteoporosis for several national and international societies.

Bibliografische Informationen